QuidelOrtho Corporation/$QDEL
1D1W1MYTD1Y5YMAX
Capital at risk
About QuidelOrtho Corporation
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
- Ticker
- $QDEL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 6,500
- Headquarters
- San Diego, United States
- Website
- www.quidelortho.com
QDEL Metrics
BasicAdvanced
$763M
-
-$15.40
0.69
-
Price and volume
Market cap
$763M
Beta
0.69
52-week high
$35.58
52-week low
$9.92
Average daily volume
1.5M
Financial strength
Current ratio
1.386
Quick ratio
0.596
Long term debt to equity
1.514
Total debt to equity
1.715
Interest coverage (TTM)
0.16%
Profitability
EBITDA (TTM)
484.6
Gross margin (TTM)
44.86%
Net profit margin (TTM)
-39.20%
Operating margin (TTM)
1.27%
Effective tax rate (TTM)
-1.79%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
0.35%
Return on equity (TTM)
-45.91%
Valuation
Price to revenue (TTM)
0.283
Price to book
0.43
Price to tangible book (TTM)
-0.84
Price to free cash flow (TTM)
-3.086
Free cash flow yield (TTM)
-32.41%
Free cash flow per share (TTM)
-3.604
Growth
Revenue change (TTM)
-2.46%
Earnings per share change (TTM)
122.63%
3-year revenue growth (CAGR)
-5.43%
10-year revenue growth (CAGR)
30.51%
3-year earnings per share growth (CAGR)
184.65%
10-year earnings per share growth (CAGR)
44.76%
What the Analysts think about QDEL
Analyst ratings (Buy, Hold, Sell) for QuidelOrtho Corporation stock.
Analyst projections of the future price of QuidelOrtho Corporation stock.
Bulls say / Bears say
Adjusted EBITDA margin expanded by 310 basis points to 20.5% in Q2 2026, demonstrating strong operational leverage and effective cost management. (Q2 Press Release)
Excluding China, total revenue grew 6% year-over-year in Q2 2026, reflecting robust underlying demand across its core labs and point-of-care markets. (Q2 Press Release)
In April 2026, QuidelOrtho completed the acquisition of LEX Diagnostics, adding an ultra-fast molecular diagnostics platform for point-of-care testing and strengthening its high-margin POC molecular portfolio. (Q1 Press Release)
Draft NHSA IVD pricing guidelines in China contributed to lower distributor purchase volumes and pressured the company’s Labs business in China during the first half of 2026, creating significant uncertainty around future sales in the region. (SEC 10-Q)
In its Q2 2026 results, QuidelOrtho cut full-year revenue guidance to $2.52 billion–$2.60 billion (from $2.70 billion–$2.75 billion) and slashed adjusted EPS guidance by over 50%, reflecting substantial pressure on growth and profitability. (Q2 Press Release)
Point of Care revenue plunged 34% in Q1 2026 due to a weaker respiratory season, underscoring the segment’s high vulnerability to cyclical disease patterns. (Q1 Press Release)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
QDEL Financial Performance
Revenues and expenses
QDEL Earnings Performance
Company profitability
Upcoming events
No upcoming events
QDEL News
AllArticlesVideos
Funds containing QDEL
AllUSDEURGBP
Fund name | Fund size | $QDEL weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.13% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.13% |
iShares Healthcare Innovation£DRDR | £1B | 0.13% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.06% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.